Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/m22-2141
Abstract: The clinical impact of coadministration of the oral SARS-CoV-2 protease inhibitor nirmatrelvir and the pharmacokinetic booster ritonavir among vaccinated populations is uncertain. This study emulated a clinical trial to assess whether nirmatrelvir plus ritonavir reduces… read more here.
Keywords: ritonavir early; plus ritonavir; covid large; nirmatrelvir plus ... See more keywords
Nirmatrelvir Plus Ritonavir for Ambulatory COVID-19: Expanding Evidence, Expanding Role
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/m22-3427
Abstract: The prevention and treatment algorithm for COVID-19 begins with vaccination. Although vaccines have proved exceptional, the need for effective therapeutics for SARS-CoV-2 infection remains: Vaccine and booster uptake is heterogeneous, infection can occur in vaccinated… read more here.
Keywords: plus ritonavir; nirmatrelvir plus; covid; death ... See more keywords